The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
Study Name on ClinicalTrials.gov (link is external) |
A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 through 11 Years With Cystic Fibrosis |
---|---|
Study Drug | VX-661/ivacaftor |
Type of Study Drug | CFTR modulator |
Study Title | A Phase 3, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Tezacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation |
Study Phase | 3 |
Study Sponsor | Vertex |
https://www.clinicaltrialsregister.eu/ctr-search/search?query=vx16-661-115 |
|
Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
Age | 6 Through 11 Years |